52 results about "Synaptic function" patented technology

The invention discloses a multicolor photoelectric response synaptic device and a preparation method thereof. The multicolor photoelectric response synaptic device is of a multi-layer structure. The multilayer structure comprises a transparent conductive electrode layer, a hole transport material layer, a lead-free perovskite layer, an electron transport material layer, an organic semiconductor charge transfer compound layer and a metal electrode layer in sequence along the light incidence direction. The preparation method comprises the steps of preparing the transparent conductive electrode layer; sequentially preparing a hole transport material layer, a lead-free perovskite layer, an electron transport material layer and an organic semiconductor charge transfer compound layer on the transparent conductive electrode layer through a spin coating method; and preparing the metal electrode layer on the organic semiconductor charge transfer compound layer through vacuum evaporation. The multicolor photoelectric response synaptic device is reasonable in structural design, can realize ultraviolet-visible-near infrared multicolor photoelectric synaptic function simulation, can realize a color identification function on red light, green light and blue light in a visible light wave band, and has a good application prospect.

Provided herein are apparatuses, systems and methods for non-invasively assessing synaptic dysfunction in a patient with Alzheimer's Disease. Transcranial magnetic stimulation (TMS) is applied to at least one brain region of the patient. A plurality of TMS evoked potentials generated in response to the TMS applied to the at least one brain region of the patient is recorded with a plurality of electroencephalography (EEG) electrodes. At least one characteristic of the plurality of TMS evoked potentials is analyzed to assess synaptic dysfunction in the patient. An indication of the synaptic dysfunction assessment of the patient is output.

The invention relates to the field of photoelectric material and device physics, and discloses a preparation method of a Ga2O3: Sn / HfOx heterojunction photoelectric sensor, and the method comprises the following steps: S1, cleaning a substrate, S2, preparing a Ga2O3: Sn thin film, S3, growing an electrode, S4, preparing an HfOx thin film, and carrying out neural synapse bionic application of the Ga2O3: Sn / HfOx heterojunction photoelectric sensor. Comprising Ga2O3: Sn / HfOx synaptic plasticity research and Ga2O3: Sn / HfOx photoelectric sensor sensing and storage calculation integrated application research. The Ga2O3: Sn thin film is prepared by adopting a sol-gel method with accurate and controllable doping amount, donor doping with controllable concentration is realized by controlling the mass of the added tin sheet, so that the photocurrent and responsivity of the photoelectric sensor are increased, the HfOx thin film is prepared by adopting a magnetron sputtering method, the photoelectric sensor with a double-layer structure is constructed, the detection rate and responsivity of the device are improved, and the photoelectric sensor is suitable for the field of photoelectric sensors. An ultraviolet signal is used to simulate a plurality of synaptic functions, including EPSC, PPF and empirical learning behaviors. Furthermore, a high-linearity light-enhanced electrical suppression behavior is realized, and a basis is provided for realizing a high-precision image recognition function.

Provided herein are devices, systems, and methods for non-invasive assessment of synaptic dysfunction in a patient with Alzheimer's disease. Transcranial magnetic stimulation (TMS) is applied to at least one brain region of the patient. A plurality of TMS-evoked potentials generated in response to the TMS applied to the at least one brain region of the patient are recorded with a plurality of electroencephalogram (EEG) electrodes. At least one characteristic of the plurality of TMS-evoked potentials is analyzed to assess synaptic dysfunction of the patient. An indication of the synaptic dysfunction assessment of the patient is output.

The invention discloses a rectification memristor with a synaptic simulation function and application thereof, and belongs to the field of artificial intelligence. The memristive device adopts a sandwich structure and is sequentially composed of an upper Ag electrode, an AgI and PbI2 functional layer and a lower ITO electrode. The memristor provided by the invention has a rectification characteristic, effectively solves the sneak current problem in crossbar integration, and ensures accurate reading of device data in an array. Meanwhile, good nerve synaptic functions including dipulse suppression, dipulse simplification, long and short range memory response and synaptic weight plasticity are achieved under circulating electric pulses, and human brain nerve synaptic processing, learning and working behaviors and the like can be simulated. According to the invention, the PbI2 material is successfully applied to integration of multiple functions of rectification, storage and neuromorphic simulation for the first time, and a new possibility is developed for application in the fields of neuromorphic simulation and artificial neural networks.

The invention belongs to the technical field of medicines, and particularly relates to novel application of a medicine for intervening an APT2 target spot. The invention provides application of a medicine for intervening in an APT2 target spot in preparation of a medicine for preventing and / or treating Tau protein palmitoylation modification reduction related diseases. The learning and memory ability of an Alzheimer's disease model mouse in which the APT2 gene is knocked out or an APT2 inhibitor is injected is improved, the tangling aggregation and neuroinflammation of Tau protein are relieved, and the expression of protein related to synaptic function is increased. Experiments show that APT2 serving as a potential target spot for treating Alzheimer's disease has a remarkable effect of improving symptoms of neurodegenerative diseases, a new direction is brought to treatment of Alzheimer's disease, development of treatment of other Tau protein palmitoylation modification reduced related diseases is promoted, and the application has a wide prospect.

The application discloses a water-soluble polymer-based proton-type memristor and a preparation method thereof. The memristor has a sandwich structure and is sequentially composed of a top electrode, an inorganic resistive switching functional layer, an organic resistive switching functional layer and a bottom electrode. The top electrode is a metal active electrode, the bottom electrode is indium tin oxide (ITO), the inorganic resistive switching functional layer is a metal oxide film, and the organic resistive switching functional layer is a doping system composed of a water-soluble polymer and a doping material. The preparation process of the proton-type memristor is reliable and stable. The obtained memristor has the characteristics of high biocompatibility and green environmental protection. The device performance consistency and environmental dependence are improved, and the simulation of bionic synaptic plasticity is greatly improved. The device can be controlled by using a low voltage, has low power consumption, and has a good bidirectional current modulation effect, so that the device provides a possibility for further enriching synaptic functions and designing flexible wearable devices.

The present invention relates to the technical field of biological medicines. Disclosed are a combined detection kit for assisting in diagnosis of Alzheimer's disease and the use. Disclosed is the combined use of at least four of amyloid β-proteins, phosphorylated Tau proteins, biomarkers of neurodegeneration or neuron damage, and biomarkers related to neuroimmune disorder, synaptic dysfunction and blood brain barrier alternation in assisting in diagnosis of Alzheimer's disease. Compared with single-biomarker detection existing in the market and the combined detection using a small number of markers disclosed in some published patents, the marker combined detection provided by the present invention achieves a higher specificity or sensitivity. The present invention establishes a brand-new algorithm model, and both AD scale rating and brain function imaging diagnosis result rating are incorporated into the algorithm model for cooperative diagnosis; under the condition of a 95% specificity, the diagnosis sensitivity thereof can reach 95%, which is far higher than that of similar products in the market.

The invention provides a bipolar switchable piezoelectric ion mechanical receptor with a built-in synapse function and a preparation method of the bipolar switchable piezoelectric ion mechanical receptor. The thermal response is realized based on the phase separation behavior of the polymer network and the ionic liquid. Another purpose of the invention is to provide a piezoelectric signal polarity regulation and control method based on a phase separation mechanism, i.e., conversion from a positive piezoelectric signal to a negative piezoelectric signal. The invention provides an ionic gel material with thermal response, which has a uniform cross-linked polymer network structure and takes hydrophobic ionic liquid as a dispersion medium. The polymer network is formed by polymerizing and cross-linking acrylate monomers, and the ionic liquid is composed of imidazole cations and fluorine-containing anions.

The invention discloses a composition for treating dysgnosia, application thereof and a medicine screening method. According to the invention, the AAV virus carrying the hCAPZA2 gene is introduced into a CAPZA2 heterozygous knockout or mutated mouse model, and the effectiveness of the AAV virus in the aspects of improving the CAPZA2 expression level, recovering the synaptic function and improving the neural behavior is verified. The invention not only provides a new hope for treating the mental disorder related to the CAPZA2 gene, but also opens up a new direction for the application of gene therapy in neurodevelopment diseases.

The application discloses a dual-mode event trigger circuit based on light detection and optical synapse, comprising a detection module and a detection module; the detection module is used for triggering based on light events or voltage events, converting received optical signals or electrical signals into current signals, and transmitting the current signals to the detection module; the detection module is used for collecting current signals and performing corresponding event detection; wherein the detection module is configured with an optoelectronic device integrating light detection and optical synapse functions, when the optoelectronic device is subjected to light and no external voltage is applied, the optoelectronic device behaves as a light detection mode, at the same time, the detection module works in a light event detection mode; when the optoelectronic device is simultaneously subjected to an external voltage and light, the optoelectronic device behaves as an optical synapse mode, at the same time, the detection module works in a voltage event detection mode. The circuit realizes dual-mode event triggering by using simple devices, has compact circuit structure, high device integration, does not need a complex multi-stage decision circuit, and effectively reduces energy consumption.

The invention relates to the technical field of memristors, in particular to a composite material memristor and a preparation method thereof, specifically, an FTO glass substrate is sequentially coated with a polyvinyl alcohol and Ti3C2Tx composite material thin film and a zirconium oxide thin film, and then a silver top electrode is deposited on the zirconium oxide thin film to form a four-layer vertical structure. The method is specially designed for a neuromorphic computing system so as to simulate the plasticity of biological synapses. Tests prove that the voltage amplitude modulation precision reaches up to 0.1 V, accurate control over the synaptic weight is ensured, meanwhile, high plasticity is shown, rapid learning and adaptation to changing input conditions can be achieved, the excellent retention characteristic of more than 5 * 104 seconds and the reliability of more than 200 IV scanning cycles are achieved, and the method is suitable for large-scale popularization and application. The memristor solves the problems that when an existing memristor simulates a biological synaptic function, the voltage modulation precision, plasticity and long-term stability are not enough.

This disclosure provides methods for treating neurodegenerative diseases and restoring neuronal synaptic function by administering adenosine-to-inosine editing modifiers.

The invention discloses a novel brain protein enzymolysis active peptide for improving concentration and application thereof. Belongs to the technical field of new active peptide preparation. According to the invention, fresh pig brain is used as a raw material for enzymolysis and purification to successfully prepare the novel active peptide PAVP through brain protein enzymolysis. Efficacy verification is further carried out on the oligopeptide PAVP, and experimental results show that the oligopeptide PAVP can remarkably prolong the time of exploration of mice on new things in a new things recognition experiment and improve the concentration degree; in order to further verify the action mechanism of the PAVP, the expression quantities of synaptic plasticity markers PSD-95, BDNF and p-CREB in a mouse body are detected on the molecular level, and experimental results show that the PAVP not only repairs the synaptic touchable injury, but also possibly further enhances the synaptic function so as to achieve the purpose of improving the concentration degree.

The invention provides a photoelectron synaptic device based on a Z-type heterojunction and a preparation method and application thereof.The photoelectron synaptic device sequentially comprises a top electrode layer, a Z-type heterojunction functional layer and a bottom electrode layer from top to bottom, and the Z-type heterojunction functional layer is formed by tightly contacting a first semiconductor material layer and a second semiconductor material layer; and energy bands of the first semiconductor material layer and the second semiconductor material layer are staggered to form a Z-shaped energy band. The photoelectron synaptic device is simple in structure, the Z-type heterojunction functional layer is designed, and a plurality of synaptic behaviors are simulated by using a unique carrier recombination mechanism of the Z-type heterojunction, so that bidirectional synaptic function simulation of inhibition / excitation under the same photostimulation can be realized only through voltage switching, and the photoelectron synaptic device is applicable to various synaptic functions. And a core thought is provided for the design of a multifunctional integrated photoelectron synaptic device.

The invention discloses a method for constructing a frontotemporal lobe degeneration animal model by using TAF15 prefabricated precursor fibers, and belongs to the technical field of biology. The TAF15PFs provided by the invention is formed by aggregation of protein fragments with an amino acid sequence as shown in SEQ ID NO.1, and can promote aggregation of TAF15 protein in the brain, induce neuronal injury and synaptic dysfunction, and lead to cognitive dysfunction and anxiety and depression-like behaviors of mice. The TAF15PFFs is injected into the prefrontal cortex of a mouse, so that the frontal-temporal lobe degeneration mouse model can be constructed. The invention provides a new animal model for pathogenesis research and therapeutic drug screening of frontotemporal lobe degeneration.

The application discloses an induction method for directional differentiation of neural stem cells into dopaminergic neurons, comprising the following steps: S1, activation and adhesion of NSCs; S2, directional induction of midbrain precursor cells; S3, directional induction of dopaminergic neurons; and S4, synaptic function maturation induction. The induction method for directional differentiation of neural stem cells into dopaminergic neurons can significantly improve the directional efficiency and lineage specificity of the midbrain precursor cells: by adding salvianolic acid B and icariin, and in cooperation with SHH, FGF8 and other induction factors, the midbrain lineage-specific signal pathway can be efficiently activated, the positive rate of the midbrain precursor cell marker LMX1A is increased to more than 76%, which is far better than 49% of the existing system, and abnormal differentiation of non-midbrain lineages is effectively inhibited.

The invention discloses application of a molecular target Ptchd1 in nerve synaptic function and consciousness regulation and related diseases. Whole genome screening finds that Ptchd1 is a key molecular target for consciousness regulation, and animal experiments prove that the target has an important regulation effect on neuronal synaptic vesicle release and consciousness disappearance caused by general anesthesia drugs. In view of the fact that Ptchd1 can regulate and control drug-induced awareness disappearance and neuronal synaptic delivery, related treatment with Ptchd1 as a target spot has significant potential values in the following fields: i) application in preparation of reagents for regulating and controlling a neuronal synaptic function and awareness regulation and control; the invention also relates to application of the pharmaceutical composition in preparation of drugs for promoting awakening after anesthesia and application of the pharmaceutical composition in preparation of drugs for promoting awakening of diseases related to disturbance of consciousness, wherein the diseases related to the disturbance of consciousness comprise vegetative people, micro-consciousness or brain injury coma.

The invention relates to the technical field of artificial synapses, in particular to a composite artificial synapse which comprises a core functional layer, the core functional layer is a composite material layer, and the composite material layer is formed by mixing a SrAl2O4-based long afterglow material and a NaYF4-based up-conversion material; eu < 2 + > and Dy < 3 + > are doped in the SrAl2O4-based long afterglow material; yb < 3 + > and Tm < 3 + > are doped in the NaYF4-based up-conversion material; under excitation of near-infrared light, the NaYF4-based up-conversion material transmits energy to the SrAl2O4-based long-afterglow material through up-conversion luminescence, so that the SrAl2O4-based long-afterglow material generates long-afterglow luminescence, and a synaptic function is realized; through thermal stimulation, the release process of defect trap electrons in the SrAl2O4-based long afterglow material is regulated and controlled, and thermally induced synaptic plasticity is realized. According to the invention, SrAl2O4: Eu < 2 + >, Dy < 3 + > and NaYF4: Yb < 3 + >, Tm < 3 + > are coupled, so that long afterglow luminescence (LPL) of near-infrared triggering and thermal regulation is realized, and information encryption, handwritten number recognition and mechanical arm gesture control are realized by artificial synapses based on photo-thermal synergistic stimulation.

The invention provides application of a related preparation of a targeted synaptic receptor in preparation of a medicine for treating intellectual disturbance, and belongs to the technical field of medicines. The invention aims at intellectual disturbance related to synaptic activity disorder, aims at excitatory or inhibitory receptors, recovers synaptic steady state and intervenes in treatment of cognitive decline. Aiming at the abnormal activation of the AMPA type glutamate receptor, the perampanel can be orally taken to recover the excitatory synaptic function and neural circuit activity balance in the brain and the cognitive levels of learning, memory and the like; aiming at abnormal inhibition of GABAA type receptors, muscarinic alcohol can be injected in the intraperitoneal cavity, and the inhibitory synaptic function and neural circuit activity level in the brain as well as cognitive levels such as learning and memory can be recovered.

The embodiment of the invention discloses a light-operated artificial synaptic device and a preparation method thereof. The artificial synaptic device comprises a substrate, a light-emitting layer and a synaptic function layer which are sequentially stacked in the thickness direction: the light-emitting layer is arranged on the substrate, and the light-emitting surface of the light-emitting layer faces the synaptic function layer; and the synaptic function layer is used for responding to the light signal emitted by the light-emitting layer and generating a conductivity change for simulating a biological synaptic behavior. According to the light-operated artificial synapse device provided by the invention, the light-emitting layer is integrated into the artificial synapse device, so that light signals do not need to be propagated for a long distance and can directly act on the synapse function layer in a directional manner, and the problem of low light coupling efficiency of the existing light-operated synapse is further solved.

The invention relates to the technical field of Gaucher disease treatment, in particular to application of nicotine in preparation of drugs for relieving, adjuvant therapy or treatment of Gaucher diseases. The invention reveals for the first time that nicotine can enhance mitochondrial autophagy mediated by a PGC1 alpha / Parkin pathway by reducing accumulation of glucosylceramide and up-regulating protein expression of PGC1 alpha and Synaptophysin in a hippocampal region, also improves synaptic function and various neurotransmitter levels, enhances learning memory and application ability, and further improves neurodegenerative diseases caused by Gaucher disease.

The invention relates to the technical field of biological medicine, in particular to a medicine for targeting cathepsin B and application of the medicine in autism treatment. The medicine is prepared into an oral or injection preparation by synthesizing a small-molecule inhibitor with high selectivity and combining with pharmaceutic adjuvants, so that the activity of cathepsin B can be effectively inhibited, neuroinflammation can be relieved, and synaptic function balance can be recovered. Experiments show that the medicine remarkably improves social behavior defects and repetitive behaviors of BTBR T + Itpr3tf / J mice, and meanwhile, the activity of cathepsin B and the level of inflammatory factors in brain tissue are reduced. The dosage of the composition is 0.1-10 milligrams per kilogram of body weight, the administration route comprises oral administration or injection, and the storage condition is that the composition is stored in a dark place at the temperature of 2-8 DEG C. The invention provides a clear action mechanism and a remarkable treatment effect.

This invention provides the application of a nutritional composition in the preparation of products that promote neural development and support the improvement of neural function. The research of this invention found that intervention in the body using a nutritional composition comprising *Bifidobacterium animalis* subsp. *lactobacterium* CP-9 and 3'-sialic acid lactose can promote the development of amygdala neuronal structure, improve neural plasticity, and enhance synaptic function, thereby promoting the formation and functional maturation of the normal amygdala structure. As a core brain region regulating emotional responses, social cognition, and stress responses, the normal development of the amygdala plays a crucial role in an individual's emotional regulation ability, social interaction behavior, cognitive function, and mental health. Therefore, this invention promotes the structural and functional development of the amygdala through nutritional intervention, ultimately improving an individual's emotional regulation ability, social interaction behavior, cognitive function, and mental health.

The invention relates to an artificial synaptic device based on chiral perovskite and a preparation method thereof. The device sequentially comprises a substrate, a comb-shaped bottom electrode, a chiral perovskite functional layer and a comb-shaped top electrode from bottom to top, wherein the projection direction of the bottom electrode comb teeth and the projection direction of the top electrode comb teeth are crossed at an angle of 90 degrees; the chemical general formula of the chiral perovskite functional layer is A < 1-x > A'x PbX3, A is a chiral organic cation, A 'is an achiral organic cation, and X is one or more of Cl <->, Br <-> and I. The device obtained by the invention can respond to a chiral optical signal and complete processing and storage of chiral information, and has an excellent brain synaptic-like function at the same time.

The invention discloses a novel active peptide composition for improving concentration and application thereof. Belongs to the technical field of novel active peptides. In the brain peptide research process, various new active peptides are extracted and prepared by taking pig brain as a raw material, and the research on related functions finds that the new active peptide PAVP has the effect of improving concentration; in addition, when the new active peptide PAVP and the VVAVPGN obtained through separation are mixed according to the mass ratio of 1: 1-1: 5, compared with the condition that the new active peptide PAVP and the VVAVPGN act independently, the exploration time of CUMS model mice on new things can be remarkably prolonged, and a synergistic interaction effect is achieved; when the two components cooperate with each other, the two components also have a synergistic effect on improving the expression quantity of PSD-95 and BDNF, which indicates that when the two components are combined, the capability of repairing synaptic plasticity injury of mice due to model construction can be remarkably improved, and the synaptic function is enhanced, which is a core molecular mechanism for improving concentration.

This invention discloses a method for constructing an animal model of frontotemporal lobe degeneration using TAF15 pre-fabricated precursor fibers, belonging to the field of biotechnology. The TAF15PFFs of this invention are formed by the aggregation of protein fragments with the amino acid sequence shown in SEQ ID NO.1. They can promote the aggregation of TAF15 protein in the brain, induce neuronal damage and synaptic dysfunction, leading to cognitive impairment and anxiety and depression-like behaviors in mice. Injecting TAF15PFFs into the prefrontal cortex of mice can construct a mouse model of frontotemporal lobe degeneration. This invention provides a new animal model for studying the pathogenesis of frontotemporal lobe degeneration and screening therapeutic drugs.

The invention provides an application of ancient-Chinese health-preserving essence in preparation of a nerve repairing medicine, and belongs to the technical field of biological medicines. The invention provides an application of ancient-Chinese health-preserving essence in preparation of a nerve repairing medicine. The ancient-Chinese health-preserving essence can improve the plasticity of nerve synapses and improve the communication capability of neurons by promoting the repair of a dendritic structure and enhancing the synaptic function. And secondly, the ancient-Chinese health-preserving essence can further improve the function of VGLUT1 and the stability of MAP2 by regulating NCAM2, so that the health of nerve synapses is promoted, and nerve repair is realized.

Embodiments of the present disclosure pertain to methods of treating or preventing a neurological disorder in a subject by administering to the subject at least one microRNA (miR-NA), at least one inhibitor of the miRNA, or combinations thereof. Additional embodiments of the present disclosure pertain to compositions that include at least one miRNA of the present disclosure, at least one inhibitor of the miRNAs of the present disclosure, or combinations thereof. In some embodiments, the composition is suitable for use in treating or preventing a neurological disorder in a subject.

The invention discloses a medicine for treating neurodevelopment disorder diseases. The invention provides a etiological treatment method capable of crossing a blood brain barrier and directly targeting neural synaptic function repair, stable expression of an exogenous TBL1XR1 gene in a plurality of key brain regions (including hippocampus, prefrontal lobe, basal ganglion and the like) can be realized, and the TBL1XR1 gene has good brain targeting property and tissue affinity, and can be applied to the field of brain diagnosis and treatment. The synaptic disorder in the nervous system and the related nerve development process can be improved, and the composition has good safety in the aspects of system and nerve immunity. The application opens up a new intervention path for the neurodevelopment disorder diseases, especially the neurodevelopment disorder diseases caused by TBL1XR1 gene mutation.